Merus/$MRUS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Merus
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
Ticker
$MRUS
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
291
Website
Merus Metrics
BasicAdvanced
$5B
-
-$4.14
1.00
-
Price and volume
Market cap
$5B
Beta
1
52-week high
$67.23
52-week low
$33.19
Average daily volume
740K
Financial strength
Current ratio
5.86
Quick ratio
5.337
Long term debt to equity
1.356
Total debt to equity
1.653
Profitability
EBITDA (TTM)
-298.553
Gross margin (TTM)
-17.37%
Net profit margin (TTM)
-506.73%
Operating margin (TTM)
-549.95%
Effective tax rate (TTM)
-3.32%
Revenue per employee (TTM)
$190,000
Management effectiveness
Return on assets (TTM)
-30.61%
Return on equity (TTM)
-58.66%
Valuation
Price to revenue (TTM)
81.741
Price to book
7.75
Price to tangible book (TTM)
7.78
Price to free cash flow (TTM)
-18.653
Free cash flow yield (TTM)
-5.36%
Free cash flow per share (TTM)
-358.23%
Growth
Revenue change (TTM)
42.77%
Earnings per share change (TTM)
50.98%
3-year revenue growth (CAGR)
1.45%
10-year revenue growth (CAGR)
44.88%
3-year earnings per share growth (CAGR)
30.42%
10-year earnings per share growth (CAGR)
-4.21%
What the Analysts think about Merus
Analyst ratings (Buy, Hold, Sell) for Merus stock.
Bulls say / Bears say
Merus has established strategic collaborations with major pharmaceutical companies, including Gilead Sciences and Eli Lilly, enhancing its growth prospects. (tipranks.com)
The company reported a substantial increase in cash and cash equivalents, reaching $433 million by the end of Q3 2024, up from $204 million at the end of 2023, providing a strong financial foundation for future operations. (tipranks.com)
Analysts have maintained a 'buy' rating on Merus, with an average price target of $85.64, indicating confidence in the company's future performance. (etfdailynews.com)
Merus reported a net loss of $99.9 million for Q3 2024, a significant increase from $23 million in the same period the previous year, primarily due to heightened research and administrative expenses. (tipranks.com)
KBC Group NV significantly reduced its holdings in Merus by 94.9% during the first quarter of 2025, potentially indicating decreased confidence from institutional investors. (marketbeat.com)
The company's general and administrative expenses increased by $23 million in 2024 compared to 2023, driven by higher personnel-related costs and consultancy expenses, which could impact profitability. (itiger.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.
Merus Financial Performance
Revenues and expenses
Merus Earnings Performance
Company profitability
Merus News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Merus stock?
Merus (MRUS) has a market cap of $5B as of July 28, 2025.
What is the P/E ratio for Merus stock?
The price to earnings (P/E) ratio for Merus (MRUS) stock is 0 as of July 28, 2025.
Does Merus stock pay dividends?
No, Merus (MRUS) stock does not pay dividends to its shareholders as of July 28, 2025.
When is the next Merus dividend payment date?
Merus (MRUS) stock does not pay dividends to its shareholders.
What is the beta indicator for Merus?
Merus (MRUS) has a beta rating of 1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.